Antonio Henriques

Most insightful investor panel at #JPMHC25! Here is their advice to biotech CEOs and entrepreneurs💡: - Resist settling for incremental change during funding scarcity; continue to dream big – Mathai Mammen, M.D., Ph.D. - Be bold and differentiated – Antoine Papiernik - Prioritize building high-quality teams over focusing solely on technology – Stephen Squinto - Adopt a long-term strategy (3-5 years), not just milestone-driven short-term plans – Nina Kjellson - Strategically balance internal development with external partnerships – Uli Stilz - Clarity is power: communicate effectively and speak the right language to investors – Frank Nestle #JPM25 #Advice #Biotech #Entrepreneur #Inspiration #JPM

91

5 Comments

Cellares’ CEO & Co-Founder, Fabian Gerlinghaus, will speak at the Day One Plenary Session of the 10th Annual CAR-TCR Summit on September 24. His talk, “Turning Capital Into Clinical Milestones: Extending Runway with the World’s First IDMO”, will challenge a common misconception in biotech: that automation is an added cost best postponed until later. Early-stage cell therapy developers face a tough reality: limited runway, expensive clinical paths, and constant pressure to deliver proof fast. Automation is often treated as something to add later, but the real barrier isn’t automation—it’s the high cost and risk of the clinical path itself. Every month and every dollar spent on manual, fragmented manufacturing only increases that risk, shortens runway, and delays patient access. Cellares understands this challenge and is here to provide a solution. Join Fabian as he introduces the Biotech Incentive Program, designed to address these challenges for early-stage cell therapy developers, helping to stretch capital further and turn funding into milestones faster. We look forward to sharing more and connecting in Boston! #CellTherapy #CARTCR #CART #Automation #CellShuttle #CellQ

146

1 Comment

Everyone in pharma is racing to launch generative AI tools, even the FDA. However, some things in life take time to flourish… 📈⚕️ As journalist Natalia Mesa outlines in her recent take for BioSpace the FDA’s recent rollout of Elsa, a large language model designed to help with clinical protocol reviews and scientific evaluations, raised some red flags ⚠️. According to Mesa’s reporting, FDA insiders described the implementation as rushed, lacking proper oversight, and prone to incorrect or partially accurate outputs. Some said Elsa wasn’t ready. Others questioned how decisions made with its help could hold up under legal or scientific scrutiny. I don’t know for sure, won’t speculate on FDA’s moves. But I can say one thing clearly: it took a decade for Insilico Medicine, to get to the most advanced and well-validated AI platform in the industry, PharmaAI. Steadily building, testing, and validating…it takes time to grow organically 🌿. For those curious, here is a brief historic note: 🧬 2014 – Founded to bring AI into aging and medicine. 📄 2016–2019 – Published foundational work; GENTRL, their early generative model, created viable molecules in under a month. 🧪 2020–2021 – Launched PharmaAI, combining tools for target discovery (PandaOmics), molecule generation (Chemistry42), and trial prediction (InClinico). 💊 2022 – AI-designed anti-fibrotic drug ISM001-055 entered Phase I trials. 📈 2023–2025 – That same drug, now named Rentosertib, reached Phase II trials—with results published in Nature Medicine in June 2025 confirming safety and initial efficacy in patients. 🚀 Over just a span of several years, PharmaAI platform enabled discovery and design of more than 30 preclinical and clinical drug candidates, and multiple new targets (see image). The lesson here is this: Insilico didn’t skip steps. It published results and AI platform mechanics relentlessly, validated with its own pipeline and client’s projects, and iterated, it took time and patience. Their tools evolved from basic algorithms to a trusted enterprise platform used by major pharma players across the globe… I think Alex Zhavoronkov and Alex Aliper could one day write a book about this roller coaster ride! Meanwhile, I feel like the FDA’s experiment with Elsa shows what happens when there is a push for a quick win in a complex area like medical AI, something Mesa’s reporting hints to… I hope they figure things out fast, the FDA is one of the most important organizations in the world, IMO. We all need them to be doing great, because the health and lives of many-many people depend on that 🙏🩺 Image credit: Insilico Medicine

76

2 Comments

🚀 Expanding the Frontiers of Industrial Biotech at Genomines 🌿🔬 At Genomines, we're pushing the boundaries of Agromining and pioneering sustainable industrial innovation—melding cutting-edge science with scalable impact. Now, as we enter our pilot-scale phase, we are honored to be guided by an exceptional Scientific Advisory Panel—a powerhouse of experts in biotechnology, agriscience, operations and industrial process innovation. Their insights will strengthen our mission to scale biology-driven solutions for a sustainable future. 🔬 Meet Our Scientific Advisory Panel : 🌾 Hartmut van Lengerich – Former Senior VP at Bayer Crop Science, leading Global Crop Protection Asset-Management. With 30+ years at Bayer, Hartmut shaped sustainable agriculture solutions across major crops and continues to drive industry change as Senior Advisor at BCG and Chairman of Moa, Oxford. 🧬 Dr. Joachim Lammel – Former Head of Agricultural Research at Yara International, with 30+ years of leadership in crop nutrition and plant science. A specialist in fertilizers and digital farming, Dr. Lammel holds an M.Sc. in Agronomy and a Doctorate in Crop Nutrition. 💡 Joerg Rehbein – With 30 years of experience in global agriculture, Joerg served as Commercial Leader at Bayer CropScience across Europe and Asia. Most recently, he was SVP of Global Crop Strategy, driving sustainable solutions for a $5B crop portfolio. 🔬 Prof. Neil Bruce – A global leader in biotechnology and environmental remediation, Prof. Bruce has pioneered the use of engineered plants for decontaminating explosive pollution for over two decades. As Director of CNAP, University of York, he drives innovation in biorefining, phytoremediation, and sustainable industrial applications. 🌱 Dr. K.K. Narayanan – Co-founder of Metahelix Life Sciences (acquired by TATA’s Rallis India) and Kottaram Agro-Foods (SOULFULL), later acquired by TATA Consumer Products. Dr. Narayanan is a visionary in AgriTech and AgBio. 💰 Dr. Saurabh Tak – Deep-tech investor and expert in biomanufacturing, green chemistry, and commercializing sustainability technologies. Dr. Tak’s work at Circulate Capital and Sagana is helping shape the future of green innovation. 🧪 Dr. Sara Thodberg – Entrepreneurial scientist with expertise in plant sustainability, aggrotech, and biomanufacturing. Dr. Thodberg bridges research and industry to drive cutting-edge innovations in sustainable agriculture. 🛠️ Dr. Clément Champion – Co-founder of MOA Technology, turning academic breakthroughs into industrial solutions in aggrotech and AI. Fabien Koutchekian Silvia Costa Gaetan de Buyer Stéphane Lopez Aidan Dunning Boney Kuriakose Ph.D. Naeimeh SOUSARAEI, PhD. Naeif Matar, PhD Mehmet Ali Recai Önal Zakaria Rifai, MS Hasan KOLKAS, PhD. Muhsin Parson Abhay Veer Singh Yanyan Zhao，PhD Rim CHAMAS Reem Mirza Nathan Pinatel Danish AHMAD Hartmut van LengerichJoerg Rehbein Joachim Lammel Narayanan Kottaram Saurabh Tak Sara Thodberg, Ph.D Clément Champion

108

16 Comments